Background: Electromagnetic navigation bronchoscopy (ENB) procedures allow physicians to access peripheral lung lesions beyond the reach of conventional bronchoscopy. However, published research is primarily limited to small, single-center studies using previous-generation ENB software. The impact of user experience, patient factors, and lesion/procedural characteristics remains largely unexplored in a large, multicenter study.
Methods/design: NAVIGATE (Clinical Evaluation of superDimension™ Navigation System for Electromagnetic Navigation Bronchoscopy) is a prospective, multicenter, global, cohort study. The study aims to enroll up to 2,500 consecutive subjects presenting for evaluation of lung lesions utilizing the ENB procedure at up to 75 clinical sites in the United States, Europe, and Asia. Subjects will be assessed at baseline, at the time of procedure, and at 1, 12, and 24 months post-procedure. The pre-test probability of malignancy will be determined for peripheral lung nodules. Endpoints include procedure-related adverse events, including pneumothorax, bronchopulmonary hemorrhage, and respiratory failure, as well as quality of life, and subject satisfaction. Diagnostic yield and accuracy, repeat biopsy rate, tissue adequacy for genetic testing, and stage at diagnosis will be reported for biopsy procedures. Complementary technologies, such as fluoroscopy and endobronchial ultrasound, will be explored. Success rates of fiducial marker placement, dye marking, and lymph node biopsies will be captured when applicable. Subgroup analyses based on geography, demographics, investigator experience, and lesion and procedure characteristics are planned.
Discussion: Study enrollment began in April 2015. As of February 19, 2016, 500 subjects had been enrolled at 23 clinical sites with enrollment ongoing. NAVIGATE will be the largest prospective, multicenter clinical study on ENB procedures to date and will provide real-world experience data on the utility of the ENB procedure in a broad range of clinical scenarios.
Trial Registration: ClinicalTrials.gov NCT02410837 . Registered 31 March 2015.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845335 | PMC |
| http://dx.doi.org/10.1186/s12890-016-0228-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A nomogram based on trauma-induced coagulopathy for predicting hospital mortality in multi-trauma patients: a retrospective study.
Intern Emerg Med
January 2025
Department of Intensive Care Unit, General Hospital of Southern Theatre Command of PLA, Guangzhou, China.
Multi-trauma presents significant challenges due to the complexity of injuries and high mortality rates. Early identification and intervention are crucial for improving outcomes in these critically injured patients. This retrospective study analyzed clinical data from multi-trauma patients admitted to the emergency department of Huiyang Sanhe Hospital between January 10, 2020, and September 30, 2022.
View Article and Find Full Text PDFPreserved ratio impaired spirometry, airflow obstruction, and their trajectories in relationship to chronic kidney disease: a prospective cohort study.
Sci Rep
January 2025
Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, No.2, Xihuan South Road, Beijing Economic and Technological Development Zone, Daxing District, Beijing, China.
Spirometry findings, such as restrictive spirometry and airflow obstruction, are associated with renal outcomes. Effects of spirometry findings such as preserved ratio impaired spirometry (PRISm) and its trajectories on renal outcomes are unclear. This study aimed to investigate the impact of baseline and trajectories of spirometry findings on future chronic kidney disease (CKD) events.
View Article and Find Full Text PDFProspective Validation of CAR-HEMATOTOX and a simplified version predict Survival in Patients with Large B-Cell Lymphoma treated with anti-CD19 CAR T-cells: data from CART-SIE study.
Transplant Cell Ther
January 2025
Chair of Hematology, University of Milan; Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano.
Background: Anti-CD19 CAR T-cells have revolutionized outcomes in relapsed/refractory large B-cell lymphomas. Long-term follow-up underscored the role of hematological toxicity in non-relapse mortality, largely driven by infections, leading to the development of the CAR-HEMATOTOX (HT) score for predicting neutropenia. The European scientific community (EHA/EBMT) later reached a consensus, defining a new entity: immune effector cell-associated hematotoxicity (ICAHT).
View Article and Find Full Text PDFOutcomes of RDAVR with Coronary Revascularization: 3-year Results from the German INCA Registry.
Thorac Cardiovasc Surg
January 2025
Rhön Klinikum Campus Bad Neustadt, Bad Neustadt, Bayern, Germany.
Background: The long-term outcomes of combined rapid-deployment aortic valve replacement (RDAVR) with coronary artery bypass graft surgery (CABG) are not well explored. We report 3-year results from the INCA registry on combined RDAVR with CABG.
Methods: INCA is a prospective, multicenter registry that enrolled 224 patients undergoing RDAVR with CABG at 10 cardiac institutions in Germany.
Objective: We are still in search of new therapeutic options for COVID-19 to prevent new infections, enable fast recovery and reduce the long-lasting symptoms or sequelae. This study aimed to investigate the short- and long-term effects of inhaled aviptadil on hospitalized, adult COVID-19 patients.
Methods: A multicenter, prospective, placebo-controlled, comparative, randomized, double-blind clinical trial was conducted.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!